Nitric oxide and endothelin-1,2 in actinic keratosis and basal cell carcinoma: changes in nitric oxide/endothelin ratio - PubMed (original) (raw)
Clinical Trial
Nitric oxide and endothelin-1,2 in actinic keratosis and basal cell carcinoma: changes in nitric oxide/endothelin ratio
P Vural et al. Int J Dermatol. 2001 Nov.
Abstract
Background: Nitric oxide (NO) is an inorganic free radical gas which has cytostatic/cytotoxic actions in tumoral tissues, including gynecologic, breast, and colon cancer. Nitric oxide is also a multifunctional signaling molecule active in many cells of the body, including endothelial cells, macrophages, monocytes, hepatocytes, mast cells, osteoblasts, and astrocytes. Endothelin-1 (ET-1) is a 21-amino acid peptide that stimulates the proliferation of vascular smooth muscle cells, fibroblasts, and keratinocytes, and plays a role in the expression of proto-oncogenes (c-myc, c-fos), which precedes cell proliferation. Similar to NO, ET is secreted by different cell types, including macrophages, monocytes, hepatocytes, endothelial cells, vascular smooth muscle cells, and various tumor cells. Elevated ET-1 levels are observed in pulmonary, hepatocellular, and prostate cancers. Actinic keratosis (AK) and basal cell carcinoma (BCC) are common skin tumors with accentuated hyperkeratinization, hyperpigmentation, and keratinocyte proliferation.
Aim: To investigate plasma NOx (nitrite/nitrate -- the end products of NO metabolism), ET, and the NOx/ET ratio in patients with AK and BCC in comparison with healthy controls.
Methods: NOx, ET, and the NOx/ET ratio were measured in 13 patients with AK, 12 patients with BCC, and in 16 healthy controls.
Results: Data analysis indicated a significant increase in plasma NOx, ET, and NOx/ET values in BCC patients in comparison with controls (P < 0.001, P < 0.05 and P < 0.001, respectively). Plasma ET levels in AK were also increased in comparison with controls (P < 0.001). When the two study groups (AK and BCC) were compared, a significant increase (P < 0.001) in the NOx/ET ratio in BCC was found.
Conclusions: The increased plasma ET and NOx levels in AK and, especially, BCC are probably the result of and/or reason for the accentuated hyperkeratinization, hyperpigmentation, and keratinocyte proliferation. The increased production of ET and NO by keratinocytes may function as growth and cytotoxic factors and potential mitogens, and may accelerate further proliferation of these skin tumors. In addition, the increased NOx/ET ratio probably reflects a disturbed equilibrium between these two substances, leading to cell damage and tumor promotion and proliferation.
Similar articles
- Lipid profile in actinic keratosis and basal cell carcinoma.
Vural P, Canbaz M, Sekçuki D, Murat A. Vural P, et al. Int J Dermatol. 1999 Jun;38(6):439-42. doi: 10.1046/j.1365-4362.1999.00625.x. Int J Dermatol. 1999. PMID: 10397583 - Expression of endothelins and their receptors in nonmelanoma skin cancers.
Zhang Y, Tang L, Su M, Eisen D, Zloty D, Warshawski L, Zhou Y. Zhang Y, et al. J Cutan Med Surg. 2006 Nov-Dec;10(6):269-76. doi: 10.2310/7750.2006.00062. J Cutan Med Surg. 2006. PMID: 17241596 - Effects of exercise training of 8 weeks and detraining on plasma levels of endothelium-derived factors, endothelin-1 and nitric oxide, in healthy young humans.
Maeda S, Miyauchi T, Kakiyama T, Sugawara J, Iemitsu M, Irukayama-Tomobe Y, Murakami H, Kumagai Y, Kuno S, Matsuda M. Maeda S, et al. Life Sci. 2001 Jul 20;69(9):1005-16. doi: 10.1016/s0024-3205(01)01192-4. Life Sci. 2001. PMID: 11508642 - Nitrosative stress in cancer therapy.
Hirst DG, Robson T. Hirst DG, et al. Front Biosci. 2007 May 1;12:3406-18. doi: 10.2741/2322. Front Biosci. 2007. PMID: 17485309 Review. - Metabolism and excretion of nitric oxide in man: basal studies and clinical applications.
Wennmalm A. Wennmalm A. Agents Actions Suppl. 1995;45:129-38. doi: 10.1007/978-3-0348-7346-8_18. Agents Actions Suppl. 1995. PMID: 7717170 Review. No abstract available.
Cited by
- Neuroendocrine factors: The missing link in non‑melanoma skin cancer (Review).
Lupu M, Caruntu A, Caruntu C, Papagheorghe LML, Ilie MA, Voiculescu V, Boda D, Constantin C, Tanase C, Sifaki M, Drakoulis N, Mamoulakis C, Tzanakakis G, Neagu M, Spandidos DA, Izotov BN, Tsatsakis AM. Lupu M, et al. Oncol Rep. 2017 Sep;38(3):1327-1340. doi: 10.3892/or.2017.5817. Epub 2017 Jul 13. Oncol Rep. 2017. PMID: 28713981 Free PMC article. Review. - Serum big endothelin-1 as a biomarker in oral squamous cell carcinoma patients: an analytical study.
Mankapure PK, Barpande SR, Bhavthankar JD, Mandale M. Mankapure PK, et al. J Appl Oral Sci. 2015 Oct;23(5):491-6. doi: 10.1590/1678-775720150125. J Appl Oral Sci. 2015. PMID: 26537720 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical